v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating activities    
Net loss $ (20,015) $ (29,830)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 3,418 4,312
Noncash lease expense 1,448 1,311
Share-based compensation expense 11,928 12,147
Intangible assets amortization 419 419
Investment amortization (136) (958)
Impairment of long-lived assets 347 0
Write-off of inventory (10) (101)
Revenue interest purchase agreement interest (655) 283
Other 14 76
Changes in operating assets and liabilities    
Accounts receivable, net 2,050 (1,864)
Inventory (1,315) 264
Prepaid expenses and other current assets (824) 489
Accounts payable and accrued liabilities (7,512) (9,665)
Operating lease right-of-use assets and liabilities (2,600) (2,035)
Deferred revenue 4,004 (3,326)
Other (98) (6)
Net cash used in operating activities (9,537) (28,484)
Investing activities    
Purchases of property and equipment (796) (1,259)
Purchases of marketable securities (38,863) (50,654)
Proceeds from maturities of marketable securities 48,802 77,486
Net cash provided by investing activities 9,143 25,573
Financing activities    
Proceeds from exercise of stock options 5,025 5,451
Proceeds from capital contributions for Digital Biotechnologies, Inc. 2,475 0
Cash provided by financing activities 7,500 5,451
Net increase in cash, cash equivalents and restricted cash 7,106 2,540
Cash, cash equivalents and restricted cash at beginning of year 73,184 50,817
Cash, cash equivalents and restricted cash at end of period 80,290 53,357
Noncash investing activities    
Purchases of equipment included in accounts payable and accrued liabilities 159 211
Supplemental disclosure of cash flow information    
Cash paid for interest 3,584 2,373
Reconciliation of cash, cash equivalents and restricted cash at end of period    
Cash and cash equivalents at end of period 77,581 50,646
Restricted cash at end of period 2,709 2,711
Total cash, cash equivalents and restricted cash at end of period $ 80,290 $ 53,357